-
Will HSBC be torn apart?
News Banking giant HSBC has pleased the market with a new dividend policy. But its top shareholder thinks it should be split in two. Matthew Partridge reports.
News -
Britain’s resilient blue chips – a refuge in the inflationary storm
News The UK's blue-chip FTSE 100 index has been the best-performing major stockmarket index so far this year.
News -
The MoneyWeek Podcast with James de Uphaugh: why shifting perceptions are good for UK stocks
Podcasts Merryn talks to James de Uphaugh of the Edinburgh Investment Trust about why a “change in perception” of energy, mining, defence and bank stocks means the UK market could be well-placed to outperform.
Podcasts -
Aston Martin fuelled by Saudi Arabian cash
News Saudi Arabia’s Public Investment Fund has injected £78m into Aston Martin and will take part in a separate £575m rights issue, making it the carmaker’s second-largest shareholder, with 17% of the shares and two seats on the board.
News -
Harry Potter publisher Bloomsbury should ride out the economic storm
Analysis Bloomsbury – publisher of the Harry Potter books – saw sales boom during lockdown, and it expects to ride out the cost of living crisis too. Rupert Hargreaves delves into the figures.
Analysis -
Whisper it – but perhaps the UK stockmarket deserves to be cheap
Sponsored The UK stockmarket is historically undervalued compared to others. But there are good reasons for that, says Max King – and investors may well be right to shun it.
SPONSORED -
The market finally seems to be getting it
Editor's letter Reality checks are coming fast to the markets, says Merryn Somerset Webb – with even 2022’s safe havens beginning to reflect recession worries.
Editor's letter -
Looking for a hedge against inflation? The FTSE 100 might be a good bet
Analysis There are no assets that will protect investors' wealth entirely against inflation. But the FTSE 100 – a global stockmarket index with a sterling hedge – could be the best of a bad bunch says Rupert Hargreaves.
Analysis -
GlaxoSmithKline’s first-quarter figures show the company is on track for the year
Analysis Latest results show that it's business as usual for pharmaceutical giant GlaxoSmithKline. Rupert Hargreaves casts his eyes over the numbers.
Analysis
